Converge Bio Secures $25M in Series A Funding Led by Bessemer, Supported by Tech Leaders from Meta, OpenAI, and Wiz

Converge Bio, a startup specializing in AI-driven drug discovery, has successfully raised $25 million in a Series A funding round. The round was led by Bessemer Venture Partners and included investment from notable executives at Meta, OpenAI, and Wiz, highlighting strong confidence from leading technology innovators.